Dr. Lizzul is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
AnaptysBio
10770 Wateridge circle
San Diego, CA 92121Phone+1 858-362-6292
Summary
- Dr. Lizzul leads the AnaptysBio development organization, including clinical medicine, clinical operations, regulatory affairs, pharmacology and toxicology functions. Prior to AnaptysBio, he has served as Global Development Lead for Inflammation at Amgen, Chief Medical Officer of Sienna Biopharmaceuticals and Senior Medical Director at Kythera Biopharmaceuticals. Dr. Lizzul served as Assistant Professor of Dermatology and conducted clinical research at Tufts Medical Center. He is a board-certified dermatologist, a faculty member of the American Academy of Dermatology and has also served on the United States Food and Drug Administration (FDA) Dermatology and Ophthalmic Drugs Advisory Committee. Dr. Lizzul received his M.D., Ph.D. in molecular genetics and M.P.H. in epidemiology from the Robert Wood Johnson Medical School at Rutgers. He has also earned an M.B.A. in entrepreneurship from the Rutgers Business School.
Education & Training
- University of California Davis HealthResidency, Dermatology, 2006 - 2009
- Greenwich Hospital/Yale UniversityInternship, Internal Medicine, 2005 - 2006
- Rutgers Robert Wood Johnson Medical SchoolClass of 2005, MD, PhD, MPH
- University of California Davis HealthChief Residency, Dermatology
- Rutgers Business SchoolMBA, Entrepreneurship
Certifications & Licensure
- NY State Medical License 2009 - 2026
- CA State Medical License 2006 - 2025
- CT State Medical License 2009 - 2025
- FL State Medical License 2009 - 2025
- MA State Medical License 2009 - 2025
- NJ State Medical License 2009 - 2025
- American Board of Dermatology Dermatology
Awards, Honors, & Recognition
- Fellow (FAAD) American Academy of Dermatology
- Fellow (FASDS) American Society for Dermatologic Surgery
Clinical Trials
- Long-term Follow-up Study of Subjects Who Completed Clinical Studies 755.1100_FA, 810.1100_FA, or 1064.1100_FA Start of enrollment: 2016 Aug 01
Publications & Presentations
PubMed
- 19 citationsImsidolimab, an anti-interleukin-36 receptor monoclonal antibody, for the treatment of generalized pustular psoriasis: results from the phase II GALLOP trial.Richard B Warren, Adam Reich, Andrzej Kaszuba, Waldemar Placek, Christopher E M Griffiths
The British Journal of Dermatology. 2023-07-17 - 26 citationsEfficacy and Safety of ATX-101 by Treatment Session: Pooled Analysis of Data From the Phase 3 REFINE TrialsSteven H. Dayan, Joel Schlessinger, Kenneth Beer, Lisa Donofrio, Derek H. Jones
Aesthetic Surgery Journal. 2018-08-16 - 22 citationsManagement of Patient Experience With ATX-101 (Deoxycholic Acid Injection) for Reduction of Submental FatJeffrey S. Dover, Jeffrey M. Kenkel, Alastair Carruthers, Paul F. Lizzul, Todd M. Gross
Dermatologic Surgery. 2016-11-01
Press Mentions
- AnaptysBio Reports HARP Phase 2 Top-Line Data of Imsidolimab in Moderate-to-Severe Hidradenitis SuppurativaSeptember 1st, 2022
- AnaptysBio Presents Updated Data from Imsidolimab Phase 2 GALLOP Trial in Generalized Pustular PsoriasisOctober 2nd, 2021
- Novel Topical Psoriasis Treatment Targets Nerve PathwaysJuly 10th, 2019
- Join now to see all
Committees
- advisory committee member, FDA- DODAC 2010 - 2012
Professional Memberships
- Fellow
- Fellow
External Links
- Anaptysbiohttp://anaptysbio.com
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: